Search
NeOnc Technologies Holdings Inc
NTHIAdd to Watchlist
5.500USD
+0.040+0.73%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
139.07MMarket Cap
LossP/E TTM
More Details of NeOnc Technologies Holdings Inc Company
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
NeOnc Technologies Holdings Inc Info
Ticker SymbolNTHI
Company nameNeOnc Technologies Holdings Inc
IPO dateMar 26, 2025
CEOHeshmatpour (Amir F)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMar 26
Address23975 Park Sorrento
CityCALABASAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91302
Phone13106637831
Websitehttps://neonc.com/
Ticker SymbolNTHI
IPO dateMar 26, 2025
CEOHeshmatpour (Amir F)
Company Executives of NeOnc Technologies Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Hon. Jim Delshad
Hon. Jim Delshad
Independent Director
Independent Director
--
--
Ms. Laurie Berman
Ms. Laurie Berman
Investor Relations
Investor Relations
--
--
Mr. Josh Neman
Mr. Josh Neman
Chief Clinical Officer
Chief Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chen (Thomas C.)
17.35%
AFH Holding & Advisory, L.L.C.
14.69%
Heshmatpour (Amir Farrokh)
14.28%
Chiang (Ming-Fu Alan)
5.56%
HighPoint Advisor Group, LLC
4.53%
Other
43.60%
Shareholders
Shareholders
Proportion
Chen (Thomas C.)
17.35%
AFH Holding & Advisory, L.L.C.
14.69%
Heshmatpour (Amir Farrokh)
14.28%
Chiang (Ming-Fu Alan)
5.56%
HighPoint Advisor Group, LLC
4.53%
Other
43.60%
Shareholder Types
Shareholders
Proportion
Individual Investor
38.92%
Corporation
18.74%
Investment Advisor
6.62%
Research Firm
1.09%
Investment Advisor/Hedge Fund
0.75%
Hedge Fund
0.27%
Pension Fund
0.06%
Other
33.55%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
23
1.79M
3.13%
--
2026Q1
35
2.40M
9.49%
+527.87K
2025Q4
23
2.01M
10.33%
+482.13K
2025Q3
17
1.61M
8.43%
+1.29M
2025Q2
18
10.40M
54.67%
-137.09K
2025Q1
15
8.72M
46.52%
+8.72M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chen (Thomas C.)
4.39M
19.33%
--
--
Feb 06, 2026
AFH Holding & Advisory, L.L.C.
3.71M
16.37%
--
--
Feb 06, 2026
Heshmatpour (Amir Farrokh)
3.54M
15.6%
--
--
Feb 06, 2026
Chiang (Ming-Fu Alan)
1.41M
6.2%
--
--
Feb 06, 2026
HighPoint Advisor Group, LLC
1.14M
5.04%
+194.41K
+20.46%
Dec 31, 2025
HCWG LLC
1.02M
4.51%
--
--
Feb 06, 2026
BofA Global Research (US)
224.29K
0.99%
-2.20K
-0.97%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
164.38K
0.72%
+15.87K
+10.68%
Dec 31, 2025
Garnett (Keithly)
161.35K
0.71%
--
--
Feb 06, 2026
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
